EMBL researchers have created a new epigenome editing platform utilizing CRISPR to alter chromatin modifications with high precision.

The platform enables in-depth research on the relationship between chromatin modifications and gene expression.

Discoveries include new functions of specific chromatin marks in the control of genes.

The technology promises advances in precision medicine through personalized epigenetic modifications.

The toolkit presents novel opportunities for exploring gene regulation and crafting therapies for various diseases.